HLA-Arena: Enabling Structure-Guided Pipelines for Personalized Cancer Immunotherapy Design

Are you interested in learning about the role of Human Leukocyte Antigens (HLA) in cancer? Join Dr. Dinler Antunes of the University of Houston as he presents the HLA-Arena tool—a computational platform that incorporates neoantigen markers and other bioinformatics pipelines to study HLA in cancer.

The HLA-Arena 2.0 environment integrates existing neoantigen discovery resources, such as pVACtools, with new AI-driven bioinformatics methods to help you predict immunogenicity, off-target toxicity, and T-cell receptor (TCR) specificity.

By leveraging structural data and accounting for biochemical properties driving TCR-peptide-HLA binding specificity, HLA-Arena can help facilitate the design of better and safer cancer vaccines and T-cell-based immunotherapies for patients with different types of cancers.

NCI’s Informatics Technology for Cancer Research Program funds HLA-Arena.